Antibody–drug conjugates have emerged as ... stages that employ payloads with distinct mechanisms of action, from immune agonist payloads to protein degrader payloads and novel cytotoxic payloads.

This results in T reg cell depletion and a restored antitumor immune response ... optimized antibody–drug conjugates, to bispecific antibodies and chimeric antigen receptors for cell-based ...

Enter the game-changer—two Pt-MSA-2 conjugates (I and II). These ingenious compounds bring together the DNA-damaging power of cisplatin and the immune-activating strength of STING agonist MSA-2.

Innovent Biologics Inc. has entered into a collaboration and exclusive license agreement with F. Hoffmann-La Roche Ltd. to advance the development of IBI-3009, a novel DLL3-targeted antibody-drug ...